Company profile
Biora Therapeutics, Inc.
PNK: BIORQ · Healthcare · Biotechnology
#1146 of 1,418 Healthcare companies by revenuebottom-decile growth
EA Score
——FH —DQ 23GM —SS 20
v0.1 · 25/100 weight · pillars only
↑ Piotroski F, workforce scale · ↓ operating margin, net margin
Methodology →Revenue TTM
$1.8M
Rev growth YoY (TTM)
+9700.0%
Net income (FY)
-$124.1M
Employees
58
as of 2026-08-29
Market cap
$452
as of 2026-08-29
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$4.0k$4.0k2023
Net income-$124.1M-$124.1M2023
Operating income-$67.1M-$67.1M2023
Total assets$31.2M$31.2M2023
Liabilities$132.6M$132.6M2023
Equity-$101.4M-$101.4M2023
Revenue trend
FY2021 – FY2023 · USD
FY21
FY21
FY21
FY22
FY22
FY22
FY22
FY23
Revenue by segment
Filed disclosures · FY2021
By product
Commercial Third Party Payors69%
Government Health Benefit Programs23%
Patient Laboratory Distribution Partners7%
By geography
Not disclosed.
The read
What is Biora Therapeutics, Inc.’s revenue?
Biora Therapeutics, Inc. booked $4.0k in FY2023 revenue, contracting 99% year over year — among the slowest-growing Healthcare companies we track, at a -3102875.0% net margin.
Peers · Healthcare
Pharmagen, Inc.——HeartSciences Inc.——Caring Brands, Inc.22DAditxt, Inc.17DAccelera Innovations, Inc——Instadose Pharma Corp.——Neighbors
San Diego →Key facts
CEOAditya Mohanty
SectorHealthcare
IndustryBiotechnology
HeadquartersSan Diego, CA
ExchangePNK: BIORQ
Employees58
IPO date2025-08-11
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.